Affiliation:
1. Ipsen Innovation, 5 avenue du Canada, Z.I. Courtabœuf, Les Ulis 91190, France
2. Ipsen Pharmsciences, 20 rue Ethé Virton, Dreux 28109, France
Abstract
Global cancer prevalence has continuously increased in the last decades despite substantial progress achieved for patient care. Cancer is no longer recognized as a singular disease but as a plurality of different ones, leading to the important choice of the drug administration route and promoting the development of novel drug-delivery systems (DDS). Due to their structural diversity, therapeutic cancer drugs present specific challenges in physicochemical properties that can adversely affect their efficacy and toxicity profile. These challenges are addressed by innovative DDS to improve bioavailability, pharmacokinetics and biodistribution profiles. Here, we define the drug delivery challenges related to oral, intravenous, subcutaneous or alternative routes of administration, and review innovative DDS, marketed or in development, that answer those challenges.
Reference173 articles.
1. World Health Organization website. Health Topics – Cancer – Overview. www.who.int/cancer/en/
2. Center Watch. FDA approved drugs for oncology. www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology
3. National Cancer Institute training module. Cancer Registration & Surveillance Modules – Cancer Treatment. https://training.seer.cancer.gov/treatment/
4. Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy
5. Challenges in the delivery of peptide drugs: an industry perspective
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献